A Comprehensive Monograph on Molecular Hydrogen (DB15127) as an Emerging Therapeutic Agent

Section 1: Physicochemical Profile and Identification

The therapeutic potential of any small molecule is fundamentally governed by its chemical structure and physical properties. In the case of molecular hydrogen (DB15127), its identity as the simplest and lightest of all molecules dictates not only its unique biological interactions but also the significant and persistent challenges associated with its formulation, administration, and clinical application. A thorough understanding of its physicochemical profile is therefore an essential prerequisite for any critical evaluation of its role in medicine.

1.1. Chemical and Structural Identifiers

Molecular hydrogen is a small molecule classified under the DrugBank accession number DB15127 [User Query]. It is the elemental form of hydrogen, existing as a diatomic molecule with the chemical formula H2​.[1] This structure consists of two hydrogen atoms covalently bonded, each comprising a single proton and a single electron in its most common isotope, protium (

1H).[2] The simplicity of this atomic and molecular structure is a defining characteristic.

Key chemical and structural identifiers are as follows:

• Chemical Formula: H2​ [1]
• Molecular Weight: 2.01588 g/mol [1]
• CAS Registry Number: 1333-74-0 [1]
• Synonyms: Dihydrogen, o-Hydrogen, p-Hydrogen, Molecular hydrogen [1]
• IUPAC Standard InChI: InChI=1S/H2/h1H [1]
• IUPAC Standard InChIKey: UFHFLCQGNIYNRP-UHFFFAOYSA-N [1]

While protium is the major isotope, hydrogen also exists in other isotopic forms, including deuterium (2H or D), which contains one proton and one neutron, and the radioactive isotope tritium (3H or T), which contains one proton and two neutrons.[2] The name "hydrogen" is derived from the Greek

hydro genes, meaning "water former," reflecting its role in the composition of water.[2]

1.2. Physical and Chemical Properties

At standard temperature and pressure, molecular hydrogen exists as a colorless, odorless, and tasteless gas.[2] It is the lightest known gas, with a vapor density of approximately 0.07 relative to air, meaning it is significantly less dense and will rise rapidly in an atmospheric environment.[2] This low density is a direct consequence of its minimal molecular weight.

Its thermodynamic properties are characterized by extremely low melting and boiling points, reflecting weak intermolecular forces. As a liquid, it exists only at cryogenic temperatures.[5] Key physical and chemical properties are summarized in Table 1.

Table 1: Physicochemical Properties of Molecular Hydrogen

Property	Value	Source(s)
Molecular Formula	H2​	1
Molecular Weight	2.01588 g/mol	1
CAS Number	1333-74-0	1
Appearance	Colorless, odorless, tasteless gas	2
Melting Point	-259.2 °C	2
Boiling Point	-252.8 °C	2
Water Solubility	1.62 mg/L (at 21 °C); 0.00017 g/100 mL	2
Vapor Density	0.07 (vs. air)	2
Autoignition Temp.	500 to 590 °C	3
Flammability Limits	LEL: 4%; UEL: 75% (in air)	7
Heat of Combustion	-285.8 kJ/mol	5
Stability	Stable under normal conditions; noncorrosive	2
NFPA 704 Ratings	Health: 0, Flammability: 4, Instability: 0	7

The poor solubility of hydrogen in water is a critical parameter that profoundly influences its therapeutic delivery. At room temperature and atmospheric pressure, the maximum achievable concentration in water is approximately 0.78 mM, which corresponds to about 1.6 mg/L or 1.6 parts per million (ppm).[6] This low solubility presents a significant challenge for administering a sufficient therapeutic dose via aqueous solutions, such as hydrogen-rich water or saline.

Chemically, molecular hydrogen is stable and relatively unreactive at ambient temperatures due to the high dissociation energy of the H-H covalent bond. This property leads to its classification as a theoretically inert gas.[2] It is also noncorrosive to most materials.[5]

1.3. Safety, Handling, and Stability Considerations

The safety profile of molecular hydrogen is paradoxical. While it is considered pharmacologically nontoxic, its physical properties present significant handling hazards, primarily related to its extreme flammability.

Flammability and Explosivity:

Hydrogen is highly flammable and readily forms explosive mixtures with air over a remarkably wide range of concentrations.2 The lower explosive limit (LEL) is 4% and the upper explosive limit (UEL) is 75% by volume in air.7 It can be easily ignited by heat, sparks, or open flames, and it burns with a pale blue, almost invisible flame, which can make detection of a fire difficult.5 The National Fire Protection Association (NFPA) 704 standard assigns hydrogen a flammability rating of 4, the highest possible level, indicating that it burns readily and vaporizes completely at normal temperatures and pressures.7 This high risk of combustion is a primary constraint in its clinical use, particularly for inhalation therapy, where concentrations are typically kept below the 4% LEL to ensure patient safety.9

Toxicity Profile:

From a biological standpoint, molecular hydrogen is considered nontoxic.2 Its only direct physiological risk is that of a simple asphyxiant. At very high concentrations in an enclosed, poorly ventilated space, it can displace oxygen in the air, leading to hypoxia.3 The American Conference of Governmental Industrial Hygienists (ACGIH) has not established a Threshold Limit Value (TLV), classifying it simply as an asphyxiant.3 This excellent pharmacological safety profile is a key advantage for its therapeutic potential.

Regulatory Classifications for Handling:

Reflecting its physical hazards, hydrogen is classified under various regulatory systems. It is assigned the Hazard Code F+ (Extremely Flammable) and is transported under UN number 1950 or 1049 with a DOT Hazard Class of 2.1 (Flammable Gas).3

These two fundamental physicochemical properties—poor aqueous solubility and a wide explosive range—create a significant and persistent challenge for the clinical development of molecular hydrogen. The former complicates the formulation of stable, therapeutically relevant doses in aqueous solutions, as the dissolved gas is prone to rapid escape.[8] The latter imposes strict safety limits on concentrations used for inhalation therapy, which may not always align with the most biologically effective dose. Consequently, the search for effective and safe delivery modalities is a central theme in hydrogen medicine, predating and often confounding the evaluation of its biological efficacy. This inherent difficulty in drug formulation and delivery is a significant hurdle that must be considered when interpreting clinical data. For instance, the instability of hydrogen in solutions suggests that the actual dose received by a patient in trials using hydrogen-rich water can be highly variable and difficult to control. This provides a critical lens through which to view conflicting clinical outcomes, such as the failure of a large Parkinson's disease trial that was later attributed to the investigational product containing no appreciable hydrogen.[11] This highlights how formulation failures, driven by these core physicochemical properties, can lead to falsely negative conclusions about biological effect.

Section 2: Comprehensive Pharmacological Profile

While historically considered biologically inert, research over the past two decades has revealed that molecular hydrogen possesses a surprisingly broad range of pharmacological activities. It is now understood to be a pleiotropic agent that exerts antioxidant, anti-inflammatory, and anti-apoptotic effects. The initial hypothesis of hydrogen as a simple, direct radical scavenger has evolved into a more nuanced view of it as a sophisticated signaling modulator that can influence fundamental cellular processes, including gene expression and mitochondrial bioenergetics.

2.1. Primary Mechanism of Action: A Selective Antioxidant

The modern era of hydrogen medicine was ignited by the landmark 2007 discovery that molecular hydrogen functions as a therapeutic antioxidant with a unique and highly advantageous property: selectivity.[12] The central hypothesis is that H₂ selectively reduces the most cytotoxic and highly reactive oxygen species (ROS), specifically the hydroxyl radical (•OH) and peroxynitrite (

ONOO−).[14]

The hydroxyl radical is the most potent oxidant species in biological systems, reacting indiscriminately with essential macromolecules such as nucleic acids, proteins, and lipids, leading to widespread cellular damage.[15] Peroxynitrite is another highly damaging oxidant involved in nitrosative stress. Unlike these species, there are no known endogenous enzymatic systems capable of efficiently neutralizing them.[15] The proposed direct scavenging reaction,

H2​+•OH→H2​O+H•, offers a mechanism by which H₂ can directly mitigate this damage.[18]

The selectivity of this action is a crucial advantage over many conventional antioxidants. H₂ does not react with or neutralize other ROS that, despite being oxidants, play essential roles as signaling molecules in normal physiological processes. These include superoxide (O2•−​), hydrogen peroxide (H2​O2​), and nitric oxide (NO•).[9] By preserving these signaling ROS, H₂ avoids disrupting normal metabolic redox reactions and cellular communication, a significant drawback of less selective, broad-spectrum antioxidants.[8] This allows H₂ to target pathological oxidative stress without interfering with physiological homeostasis.

2.2. Anti-Inflammatory and Immunomodulatory Effects

Beyond its antioxidant properties, molecular hydrogen has demonstrated potent and consistent anti-inflammatory activity across a wide array of preclinical models, including those for sepsis, ischemia-reperfusion injury, and various chronic inflammatory diseases.[6] This effect is not merely a downstream consequence of reducing oxidative stress but involves direct modulation of inflammatory pathways.

A key mechanism is the regulation of cytokine production. H₂ has been shown to suppress the expression and release of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6).[13] These cytokines are central mediators of the inflammatory cascade in numerous diseases.

At the molecular level, H₂ can inhibit critical inflammatory signaling pathways. The most notable of these is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. NF-κB is a master transcriptional regulator of inflammation. H₂ has been shown to inhibit its activation, in part by preventing the phosphorylation and subsequent degradation of its inhibitor, IκBα.[18] By keeping the NF-κB complex sequestered in the cytoplasm, H₂ prevents the transcription of a wide range of inflammatory genes, including those for cytokines, chemokines, and adhesion molecules. This immunomodulatory capacity suggests H₂ can help quell excessive inflammatory responses that drive tissue damage.

2.3. Modulation of Apoptotic and Autophagic Pathways

Molecular hydrogen exerts significant cytoprotective effects by regulating programmed cell death pathways, primarily apoptosis. The ability to inhibit apoptosis is a key component of its therapeutic action in conditions characterized by excessive cell death, such as ischemia-reperfusion injury and neurodegeneration.[6]

This anti-apoptotic effect is achieved through the modulation of the expression and activity of key regulatory proteins in the apoptotic cascade. Specifically, H₂ has been shown to upregulate the expression of anti-apoptotic proteins from the Bcl-2 family, such as Bcl-2 itself and Bcl-xL. Concurrently, it downregulates the expression of pro-apoptotic proteins, including Bax and the executioner caspases, such as caspase-3, caspase-8, and caspase-9.[13] By shifting the balance of these regulatory factors in favor of survival, H₂ helps preserve cellular integrity in the face of pathological stress.

In addition to apoptosis, H₂ also influences autophagy, the cellular process of self-degradation and recycling of damaged organelles and proteins. This process can be either protective or detrimental depending on the context. In a model of myocardial ischemia-reperfusion injury, hydrogen-rich saline was found to alleviate tissue damage by inducing PINK1/Parkin-mediated mitophagy, a selective form of autophagy that specifically removes damaged mitochondria.[20] This suggests H₂ can promote protective forms of autophagy to clear dysfunctional components and maintain cellular health.

2.4. Influence on Cellular Signaling and Gene Expression

While the selective antioxidant theory was foundational, a growing body of evidence indicates that the therapeutic effects of molecular hydrogen cannot be explained by direct radical scavenging alone. The reaction kinetics of H₂ with the hydroxyl radical are relatively slow compared to other cellular antioxidants, suggesting that other mechanisms are at play.[17] It is now widely accepted that H₂ also functions as a novel signaling molecule, or "gasotransmitter," capable of modulating protein phosphorylation cascades and altering the expression of a multitude of genes.[16]

A critical signaling pathway modulated by H₂ is the Keap1-Nrf2 system. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription factor that regulates the cellular antioxidant response. Under normal conditions, Nrf2 is bound by its inhibitor, Keap1, and targeted for degradation. In the presence of oxidative or electrophilic stress—or, as studies show, in the presence of H₂—Nrf2 is released, translocates to the nucleus, and binds to the antioxidant response element (ARE) in the promoter region of its target genes.[17] This initiates the transcription of a broad suite of over 200 cytoprotective genes, including those for key endogenous antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and heme oxygenase-1 (HO-1).[20] This activation of the Nrf2 pathway represents a powerful, indirect antioxidant mechanism that amplifies H₂'s protective effects and contributes to a more robust and lasting cellular defense against oxidative stress.

Beyond Nrf2, H₂ has also been shown to influence other major signaling pathways involved in cell survival, proliferation, and inflammation, including the mitogen-activated protein kinase (MAPK) pathways, the PI3K/Akt pathway, and the JNK pathway.[18] This ability to act as a broad-spectrum signaling modulator, rather than a simple chemical scavenger, helps to explain its pleiotropic effects across a wide range of disease models. This re-framing of H₂ from a passive antioxidant to an active biological regulator has profound implications for research, suggesting that future studies should focus on identifying its primary molecular targets, which may include metalloproteins, rather than solely measuring its effect on downstream oxidative stress markers.[18]

2.5. Impact on Mitochondrial Function and Bioenergetics

Mitochondria are central to cellular metabolism and are also the primary source of endogenous ROS production. As such, they are a key site of oxidative damage and a critical target for therapeutic intervention. Due to its small size and high diffusivity, molecular hydrogen can easily penetrate mitochondrial membranes to exert its protective effects directly at the source of ROS generation.[8]

Beyond simply neutralizing radicals within the mitochondria, H₂ appears to have a more profound effect on mitochondrial function and cellular bioenergetics. Several studies report that H₂ can stimulate energy metabolism.[12] It has been shown to enhance mitochondrial membrane potential, increase the activity of mitochondrial respiratory chain complexes, and ultimately boost the production of adenosine triphosphate (ATP), the cell's primary energy currency.[20] This suggests that H₂ can not only protect mitochondria from damage but also improve their functional efficiency, which is particularly beneficial in pathological states characterized by mitochondrial dysfunction and energy deficits.

The pleiotropic nature of H₂—acting on antioxidant, anti-inflammatory, and anti-apoptotic pathways simultaneously—is a defining feature. This broad activity explains its promising effects in over 170 different disease models, as these pathways are fundamental to a vast number of pathologies.[30] However, this same quality presents a significant challenge from a pharmaceutical development and regulatory perspective. Conventional drug development favors a "one drug, one target" approach for achieving specificity and a clear mechanism of action. The lack of a single, well-defined primary target makes H₂ a "pharmacological multitool" rather than a "precision scalpel." This creates a disconnect between the enthusiastic preclinical literature and the slow, difficult path to clinical translation, as designing pivotal Phase 3 trials for a molecule with such broad effects is inherently complex.

Section 3: Pharmacokinetics and Administration Modalities

The therapeutic efficacy of molecular hydrogen is intrinsically linked to its pharmacokinetic profile—how it is administered, absorbed, distributed throughout the body, and ultimately eliminated. Its unique physical properties, particularly its small size and high diffusivity, grant it unparalleled distribution capabilities but also lead to rapid clearance. Understanding the nuances of its ADME (absorption, distribution, metabolism, and excretion) profile and the comparative advantages of different administration routes is critical for designing effective dosing regimens and for interpreting the outcomes of clinical studies.

3.1. Routes of Administration: A Comparative Analysis

Several methods have been developed to deliver therapeutic doses of molecular hydrogen, each with distinct characteristics, advantages, and limitations. The choice of administration route can significantly influence the resulting pharmacokinetic profile and, consequently, the primary site of therapeutic action. A comparative overview is presented in Table 2.

Table 2: Comparative Overview of Hydrogen Administration Routes

Feature	Inhalation	Hydrogen-Rich Water (HRW)	Hydrogen-Rich Saline (HRS)
Route	Respiratory (non-invasive)	Oral (non-invasive)	Intravenous/Intraperitoneal (invasive)
Bioavailability	High, rapid systemic access	Moderate, subject to GI absorption	High, direct systemic access
Time to Peak	~30 minutes	5-15 minutes	<5 minutes
Duration of Effect	Sustained during inhalation	Transient	Rapid peak, transient
Primary Target	Lungs, brain, heart (highly perfused)	GI tract, liver (portal circulation)	Systemic, rapid delivery to all organs
Advantages	Direct, controlled dosing, rapid systemic effect	Portable, convenient, safe, non-invasive	Precise dosing, rapid delivery, clinical control
Disadvantages	Flammability risk (>4%), requires equipment	Low H₂ solubility, unstable dose, large volumes	Invasive, risk of infection, clinical setting only
Source(s)	12	8	8

• Inhalation of H₂ Gas: This method provides direct and rapid systemic delivery of hydrogen. To ensure safety and avoid the risk of explosion, the concentration of H₂ is typically kept below its lower flammability limit of 4% in air.[33] However, in certain supervised clinical settings, such as the protocol for COVID-19 treatment in China, much higher concentrations (e.g., 66.6% H₂ with 33.3% O2​) have been utilized.[31] Inhalation is particularly effective for targeting the respiratory system and highly perfused organs like the brain.[21]
• Drinking Hydrogen-Rich Water (HRW): This is the most common, convenient, and accessible method for non-clinical use.[12] H₂ gas is dissolved into water, typically reaching a saturation point of around 1.6 ppm (0.8 mM) under standard conditions.[6] While it is safe and portable, the primary challenges are the low solubility of H₂ in water and the instability of the solution, as the dissolved gas rapidly escapes into the atmosphere. This can lead to significant variability in the actual dose consumed.[8]
• Injection of Hydrogen-Rich Saline (HRS): This invasive method is reserved for clinical and experimental settings. H₂ is dissolved in sterile saline, which can then be administered intravenously or intraperitoneally.[12] HRS allows for the precise control of dosage and provides rapid, direct entry into the systemic circulation, bypassing the gastrointestinal tract.[31]
• Topical/Transdermal Administration: This category includes methods like bathing in hydrogen-rich water, applying hydrogen-infused gels, or using hydrogen-rich eye drops.[8] Due to its small size, H₂ can penetrate the skin and enter the bloodstream, achieving systemic distribution. This route is being explored for dermatological conditions and localized injuries.[21]

3.2. Absorption, Distribution, Metabolism, and Excretion (ADME) Profile

The ADME profile of molecular hydrogen is defined by its unique physical characteristics.

• Absorption and Distribution: As the smallest molecule in existence, H₂ exhibits absorption and distribution properties superior to almost any other therapeutic agent.[12] Its low molecular weight, neutral charge, and nonpolar nature allow it to diffuse effortlessly and rapidly across biological membranes through passive diffusion.[16]
• Unparalleled Penetration: A key therapeutic advantage is its ability to cross barriers that are impermeable to most other drugs, including the blood-brain barrier and the placental barrier.[12] This allows it to reach otherwise difficult-to-target tissues.
• Subcellular Distribution: H₂ can readily penetrate into subcellular compartments, including the mitochondria and the nucleus.[8] This allows it to exert its antioxidant and signaling effects at the very sites where oxidative stress originates and where genetic regulation occurs.
• Pharmacokinetic Dynamics: The route of administration dictates the initial pharmacokinetic profile. Ingestion of HRW leads to a rapid peak in breath and plasma H₂ concentration within 5-15 minutes.[12] Inhalation results in a slower rise to a steady-state plasma level, which is reached in approximately 30 minutes and maintained for the duration of inhalation.[12]
• Metabolism: Molecular hydrogen is considered metabolically inert in mammals. Human cells lack the hydrogenase enzymes necessary to catalyze reactions involving H₂.[6] It is not broken down or incorporated into other molecules and does not interfere with fundamental physiological parameters such as body temperature, blood pressure, or blood pH.[31]
• Excretion: The primary route of excretion for exogenous hydrogen is via the lungs. Once administration ceases, the concentration gradient reverses, and H₂ rapidly diffuses from the blood into the alveoli and is exhaled. Following inhalation, H₂ levels in the body typically return to baseline within about 60 minutes.[12] A portion of endogenously produced H₂ from gut microbiota also enters the circulation and is excreted in the breath.[12]

The pharmacokinetic profile of H₂, characterized by rapid absorption and even more rapid elimination, presents a compelling paradox. The molecule is a transient guest in the body, yet it is being investigated for chronic conditions that would seem to require a sustained therapeutic presence. This apparent contradiction strongly suggests that H₂ does not need to be continuously present to exert its effects. Instead, it likely acts as a trigger, initiating a "hit-and-run" pharmacodynamic mechanism. By briefly activating durable downstream signaling pathways, such as the Nrf2 antioxidant response system, H₂ can induce a protective state that persists long after the gas itself has been cleared from the body.[19] This has significant implications for dosing strategies, suggesting that the frequency of administration—to repeatedly "trigger" these protective cascades—may be more critical for therapeutic success than achieving a high, sustained peak concentration.

Furthermore, the different administration routes are not merely interchangeable delivery systems; they logically determine the primary site of action and, therefore, the most appropriate therapeutic targets. Drinking HRW delivers the highest initial H₂ concentration to the gastrointestinal tract and, via the portal vein, to the liver. This makes it a rational choice for investigating conditions involving the gut-liver axis, such as metabolic syndrome and non-alcoholic fatty liver disease.[21] In contrast, inhalation delivers H₂ directly to the lungs and into the arterial circulation, providing rapid access to highly perfused organs like the brain and heart. This makes it a more suitable approach for acute conditions such as respiratory distress, stroke, and cardiac arrest.[21] A rational alignment of the administration route with the pathophysiology of the target disease is therefore essential for the design of effective clinical trials.

Section 4: Critical Review of Preclinical and Clinical Evidence

The therapeutic potential of molecular hydrogen has been explored in over 170 different human and animal disease models, resulting in a vast and rapidly growing body of literature.[30] However, the quality and conclusiveness of this evidence vary significantly across different therapeutic areas. A critical analysis reveals that while H₂ shows remarkable promise in certain acute conditions, its efficacy in chronic diseases is less clear and often confounded by methodological challenges. The following sections provide a critical review of the evidence in key areas of investigation, summarized in Table 3.

Table 3: Summary of Key Clinical Trials for Molecular Hydrogen Therapy

Indication	ClinicalTrials.gov ID	Phase	Status	Administration	Key Finding/Outcome	Source(s)
Parkinson's Disease	NCT03971617	2/3	Terminated	Not specified	Trial terminated; reasons not provided.	39
Parkinson's Disease	N/A (Pilot)	N/A	Completed	HRW (1 L/day)	Significant improvement in UPDRS scores vs. placebo.	11
Parkinson's Disease	N/A (Larger Trial)	N/A	Completed	HRW	No significant difference from placebo; attributed to lack of H₂ in water.	11
Mild Cognitive Impairment	N/A	N/A	Completed	HRW (300 mL/day)	No significant improvement in ADAS-cog scores overall. Potential minor benefit in ApoE4 carriers.	11
Acute Cerebral Infarction	N/A	N/A	Completed	H₂ Gas Inhalation (3%)	Less severe neurological impairment compared to controls.	11
Acute Cerebral Infarction	N/A	Non-controlled	Completed	HRS Infusion	Only marginally faster recovery rate.	11
Healthy Volunteers	NCT04046211	1	Completed	H₂ Gas Inhalation	Confirmed safety of inhaled hydrogen gas mixtures.	42
Rheumatologic/Metabolic	N/A	N/A	Unknown	Not specified	Trial to evaluate safety in these patient populations.	43
Low-Grade Glioma	NCT04166409	3	Recruiting	Multi-drug regimen	H₂ is a component of a combination therapy with Selumetinib, Carboplatin, etc.	44
Lymphatic Filariasis	NCT01905423	N/A	Completed	Multi-drug regimen	H₂ was part of a mass drug administration optimization trial.	45
Onychomycosis	NCT00459537	3	Completed	Topical	H₂ was a component in a topical formulation with Terbinafine.	46

4.1. Ischemia-Reperfusion Injury (IRI)

Ischemia-reperfusion injury is arguably the most robustly supported therapeutic application for molecular hydrogen. IRI occurs when blood supply is restored to tissue after a period of ischemia, paradoxically leading to a massive burst of ROS and a severe inflammatory response that causes extensive tissue damage.[38]

• Preclinical Evidence: An overwhelming body of preclinical evidence demonstrates that H₂ administration can significantly mitigate IRI in virtually every organ system studied, including the brain, heart, liver, kidneys, lungs, and intestines.[12] Animal models consistently show that H₂ reduces infarct size, decreases markers of oxidative stress (e.g., MDA, 8-OHdG), suppresses inflammatory cytokine production, and inhibits apoptosis in the affected tissue.[38]
• Clinical Evidence: This strong preclinical rationale is supported by emerging human data. Clinical studies have shown that H₂ inhalation can improve neurological outcomes in patients with post-cardiac arrest syndrome and acute cerebral infarction.[38] These benefits are associated with a reduction in circulating markers of oxidative stress and inflammation.[38]
• Analysis: The therapeutic rationale for H₂ in IRI is exceptionally strong, as the pathophysiology of the condition—an acute, overwhelming burst of oxidative stress—aligns perfectly with H₂'s primary mechanisms of action. The consistency between extensive animal data and early clinical trials makes IRI the most promising area for the future clinical development of molecular hydrogen.

4.2. Neurodegenerative Disorders

The application of H₂ for chronic neurodegenerative disorders has been an area of intense interest, but the clinical evidence remains weak and, in some cases, contradictory.

• Parkinson's Disease (PD): The clinical evidence for H₂ in PD is a case study in the challenges facing the field. An initial, small-scale pilot study (n=18) reported that patients drinking 1 L/day of hydrogen-rich water showed a statistically significant improvement in Unified Parkinson's Disease Rating Scale (UPDRS) scores over 48 weeks, whereas the placebo group worsened.[40] This promising result, however, was not replicated in a subsequent, larger trial (n=179), which found no significant difference between the H₂ and placebo groups.[11] Critically, a post-hoc analysis of the larger trial revealed that the investigational product used did not contain appreciable levels of hydrogen, rendering the study inconclusive regarding H₂'s efficacy and instead highlighting a critical failure in formulation and quality control.[11] A Phase 2/3 trial (NCT03971617) was also initiated but was later terminated for reasons not specified in the available data.[39]
• Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): The evidence here is largely unsupportive of a therapeutic benefit in established disease. A one-year, randomized controlled trial in 73 patients with MCI found that daily consumption of 300 mL of HRW did not result in any significant improvement in overall cognitive scores (as measured by ADAS-cog) compared to placebo.[11] A small, statistically significant improvement was noted in a subgroup of patients carrying the ApoE4 genetic risk factor, but this is likely a spurious finding due to the small sample size.[11] Preclinical models support this clinical picture: while H₂ can reduce oxidative stress and neuroinflammation in animal models of AD, it does not affect the core pathologies of amyloid-beta plaques and tau tangles, nor can it repair existing neuronal damage.[11]
• Analysis: A clear pattern emerges from the collective evidence on neurodegeneration. H₂ appears to be most effective in mitigating acute insults characterized by a sudden rise in oxidative stress, such as IRI. In contrast, its efficacy in chronic, progressive diseases like AD and PD is far less convincing. This aligns with a "hit-and-run" signaling mechanism; H₂ can effectively buffer an acute pathological event and trigger protective responses, but it appears unable to reverse years of accumulated damage or halt a complex, multifactorial disease process once it is well-established. This suggests that the future clinical development of H₂ should prioritize acute care settings (e.g., emergency medicine, surgery, transplantation) over chronic disease management.

4.3. Metabolic Syndrome and Associated Pathologies

Metabolic syndrome—a cluster of conditions including obesity, insulin resistance, dyslipidemia, and hypertension—is fundamentally linked to chronic low-grade inflammation and systemic oxidative stress, making it a rational target for H₂ therapy.[26]

• Clinical Evidence: Several small-scale clinical studies have yielded promising results. A study in subjects with potential metabolic syndrome found that drinking HRW for 8 weeks led to a 39% increase in the endogenous antioxidant enzyme superoxide dismutase (SOD) and a 43% decrease in urinary markers of oxidative stress (TBARS). Participants also showed an 8% increase in HDL-cholesterol and a 13% decrease in the total cholesterol/HDL ratio.[50] Other pilot studies in patients with non-alcoholic fatty liver disease (NAFLD) or in overweight women have demonstrated that high-concentration HRW can significantly decrease liver fat, reduce body fat percentage, and lower fasting insulin levels.[26]
• Analysis: This is a promising therapeutic area. The consistent positive signals across multiple small human studies on various components of metabolic syndrome are encouraging. However, the studies to date have been limited by small sample sizes and short durations. Large, long-term, well-controlled randomized trials are essential to confirm these preliminary benefits and to establish H₂ as a viable therapeutic or preventative strategy for this highly prevalent condition.[26]

4.4. Applications in Oncology

The role of hydrogen in oncology is primarily being investigated not as a standalone anti-cancer agent, but as an adjuvant to conventional therapies.

• Preclinical Evidence: The very first report on H₂'s therapeutic potential in 1975 demonstrated that hyperbaric hydrogen could cause regression of skin squamous cell carcinoma in mice.[12] More recent preclinical studies have suggested that H₂ possesses anti-proliferative and pro-apoptotic effects in certain cancer cell lines.[52]
• Clinical Role as an Adjuvant: The most compelling application is in mitigating the debilitating side effects of radiotherapy and chemotherapy. These treatments often induce significant oxidative stress in healthy tissues, leading to toxicity. Clinical studies have suggested that drinking HRW during radiation therapy can improve quality of life and reduce oxidative stress markers in patients with liver tumors, without compromising the anti-tumor efficacy of the radiation.[52] This selective protection of healthy tissue from treatment-induced damage represents a significant potential benefit for cancer patients.
• Other Trials: H₂ has also been included as a component in complex, multi-drug regimens for clinical trials investigating treatments for conditions such as low-grade glioma (NCT04166409) and lymphatic filariasis (NCT01905423).[44] In these contexts, its specific contribution to the overall therapeutic effect is difficult to isolate.

4.5. Other Investigated Therapeutic Areas

The broad mechanism of action of H₂ has led to its investigation in a diverse range of other conditions. Clinical trials have been conducted or are underway to evaluate its safety and potential efficacy in rheumatologic disorders, soil-transmitted helminth infections, and onychomycosis, often as part of a combination therapy.[43] A completed Phase 1 trial in healthy volunteers has confirmed the safety of inhaled hydrogen gas mixtures, providing foundational support for its use in further clinical investigations.[42]

Section 5: Safety, Tolerability, and Contraindications

A defining characteristic of molecular hydrogen as a therapeutic agent is its exceptional safety profile. Across hundreds of preclinical and dozens of clinical studies, H₂ has been shown to be remarkably well-tolerated with no evidence of significant pharmacological toxicity. However, a comprehensive safety assessment requires a nuanced understanding of its physical hazards, the rare and mild adverse events reported, and the specific patient populations for whom its use may be contraindicated due to its biological activities.

5.1. Consolidated Safety Profile and Adverse Event Analysis

The overwhelming consensus from the available literature is that molecular hydrogen has an excellent safety profile.[21] Its use in deep-sea diving since the 1940s at very high partial pressures has established a long history of human tolerance without long-term toxic effects.[10] Clinical trials using therapeutic doses have consistently reported no clinically significant adverse events.[33]

• General Tolerability: H₂ administration, whether via inhalation, ingestion of HRW, or injection of HRS, does not cause significant changes in vital signs (blood pressure, heart rate, respiratory rate), body temperature, blood pH, or oxygen saturation.[31] It is considered physiologically inert in that it does not directly interfere with fundamental homeostatic processes.[31]
• Adverse Events: The adverse events that have been reported are consistently described as rare, mild, and transient.[54]
• Gastrointestinal Effects: The most frequently cited adverse events are mild gastrointestinal complaints, such as loose stool, diarrhea, or bloating.[55] These have been reported by a very small percentage of participants in clinical trials. It is noteworthy that many of these reports originate from a single study that used a magnesium-based method to generate H₂ in water, which may introduce confounding factors.[55]
• Neurological Effects: Occasional reports of mild, temporary headaches or dizziness have been noted, sometimes occurring when individuals first begin H₂ therapy.[54]
• Lack of Serious Adverse Events: In a rigorous safety study involving prolonged (72-hour) inhalation of 2.4% H₂ in healthy adults, no clinically significant adverse events were observed, and no meaningful changes were found in vital signs, pulmonary function tests, neurological examinations, or a comprehensive panel of laboratory tests.[33]

5.2. Contraindications and Considerations for Special Populations

While H₂ is not pharmacologically toxic, its biological activities mean that its use may be inappropriate or require caution in certain patient populations. The majority of these "contraindications" arise not from a risk of toxicity, but from the potential for H₂ to interact with an underlying pathophysiology or concomitant medical treatment.

• Bacterial Overgrowth Conditions: A key theoretical and practical consideration is in patients with conditions characterized by anaerobic bacterial overgrowth, such as Small Intestinal Bacterial Overgrowth (SIBO) or active Clostridium difficile infection. Since many gut anaerobes can utilize H₂ as an energy source for their metabolism, the administration of exogenous hydrogen could potentially fuel their proliferation and exacerbate symptoms like bloating, abdominal pain, and malabsorption.[61]
• Patients on Monitored Medications: Because H₂ has demonstrated effects on metabolic parameters, caution is warranted for patients on medications that require precise dosage monitoring. For example, in a diabetic patient taking insulin, the potential glucose-lowering effect of H₂ could increase the risk of hypoglycemia if the insulin dose is not adjusted accordingly.[59] Similarly, its potential to influence vascular function could necessitate adjustments to antihypertensive medications to avoid hypotension.[57] This is not a side effect in the traditional sense, but rather an indication of a true pharmacological effect that requires clinical management.
• Patients with Implants or on Immunosuppressive Therapy: Theoretical concerns have been raised for patients with metallic implants, as H₂ could potentially alter the surface properties of the metal, though this is not well-supported by evidence.[61] A more plausible concern exists for patients on immunosuppressive therapy, such as organ transplant recipients. Given H₂'s immunomodulatory and anti-inflammatory effects, it could theoretically interfere with the intended action of immunosuppressant drugs.[58]

5.3. Toxicity and Overdose Assessment

Molecular hydrogen has no known pharmacological toxicity, and no upper safety limit for its consumption has been established.[29]

• Lack of Inherent Toxicity: Decades of use in deep-sea diving and numerous clinical trials have affirmed that H₂ does not cause toxic effects, even at concentrations hundreds of times higher than those used therapeutically.[29] It does not bind to hemoglobin and therefore does not induce heme-related toxic effects, a risk associated with other medical gases like carbon monoxide.[10]
• Asphyxiation Risk: The only direct toxicity risk associated with hydrogen is physical, not pharmacological. As a gas, it can act as a simple asphyxiant by displacing oxygen in the ambient air in enclosed, unventilated spaces. This is a general risk for all compressed gases and is not specific to a biological interaction.[3]
• Distinction from Other Hydrogen-Containing Compounds: It is imperative to distinguish molecular hydrogen (H2​) from other chemical compounds containing hydrogen that are highly toxic. Hydrogen peroxide (H2​O2​), for example, is a strong oxidant that can cause severe tissue damage and poisoning upon ingestion or inhalation.[62] Similarly, hydrogen sulfide ( H2​S) is a highly toxic gas with a distinct mechanism of toxicity.[63] Confusion between these distinct chemical entities must be avoided.

The exceptional safety profile of molecular hydrogen is one of its most compelling therapeutic advantages. However, this same attribute may paradoxically hinder its path to formal drug approval. Because it is so safe, H₂ is already widely available in a largely unregulated global wellness market in the form of water ionizers, hydrogen-generating tablets, and inhalation devices.[60] This widespread availability and perception as a "supplement" significantly reduces the financial incentive for pharmaceutical companies to undertake the costly and lengthy process of conducting rigorous, large-scale clinical trials required to gain regulatory approval as a prescription drug for a specific medical indication. This creates an economic and regulatory "valley of death," where a promising and safe molecule may struggle to achieve the highest level of scientific validation needed for integration into mainstream medicine.

Section 6: Regulatory Landscape, Research Gaps, and Future Prospects

The journey of molecular hydrogen from a supposedly inert gas to a promising therapeutic agent is marked by both significant scientific progress and formidable challenges. Its future role in medicine will be determined not only by the strength of the clinical evidence but also by its ability to navigate a complex regulatory landscape, address critical research gaps, and overcome the unique economic hurdles posed by its exceptional safety and widespread availability.

6.1. Current Regulatory Status

The regulatory status of molecular hydrogen is ambiguous and varies depending on its intended use and jurisdiction. This creates a challenging environment for its development as a legitimate medical therapy.

• United States (Food and Drug Administration - FDA):
• In the U.S., hydrogen's regulatory classification is bifurcated. In 2014, the FDA responded to GRAS Notice No. 520 with "no questions," effectively granting Generally Recognized as Safe (GRAS) status for the use of hydrogen gas as an ingredient in drinking water, flavored beverages, and soda drinks at levels up to 2.14% by volume.[17] This GRAS status pertains to its use as a food substance and explicitly does not constitute an approval for any medical use or therapeutic claim.[66]
• Conversely, when intended for a therapeutic purpose, medical gases are regulated by the FDA as drugs under the Federal Food, Drug, and Cosmetic Act.[67] A specific list of "designated medical gases" (e.g., oxygen, nitrogen, medical air) exists under Section 575 of this act, which allows for a streamlined certification process. Molecular hydrogen is not on this list.[68] Therefore, for H₂ to be legally marketed in the U.S. for the treatment or prevention of any disease, it would be required to undergo the full and rigorous New Drug Application (NDA) process, including comprehensive Phase 1, 2, and 3 clinical trials.
• Europe (European Medicines Agency - EMA):
• The available evidence indicates that molecular hydrogen (H2​) does not have a specific regulatory status as a medicinal gas within the European Union. Searches of EMA databases and guidelines do not show any marketing authorization, scientific opinion, or evaluation for H₂ for therapeutic use.[69] The EMA has a well-defined regulatory framework for medicinal gases, outlined in documents such as the Guideline on Medicinal Gases: Pharmaceutical Documentation (CPMP/QWP/1719/00), but H₂ is not mentioned.[71] References to "hydrogen" in EMA documents typically pertain to other compounds, such as hydrogen peroxide or potassium hydrogen carbonate.[73]
• For H₂ to be approved as a medicinal product in the EU, it would need to go through the EMA's centralized authorization procedure, which involves a rigorous scientific evaluation of its quality, safety, and efficacy for a specific indication.[69] There is no indication that H₂ has entered this pathway.

This dual status, particularly in the U.S., creates a regulatory paradox. It is legally sold for human consumption as a food ingredient but cannot be legally marketed with any medical claims. This ambiguity fuels the wellness market while simultaneously creating a high barrier to entry for legitimate pharmaceutical development.

6.2. Critical Analysis of Research Limitations and Future Directions

Despite over 2,000 publications, the field of hydrogen medicine is still in its relative infancy and is characterized by several critical limitations that must be addressed to advance its clinical translation.[30]

• Key Research Gaps and Limitations:

1. Undefined Primary Mechanism: The most significant scientific gap is the lack of a clearly defined primary molecular target and mechanism of action. While its effects on ROS, inflammation, and apoptosis are well-documented, the upstream event that initiates these pleiotropic effects remains elusive.[21] This hinders rational drug development and regulatory acceptance.
2. Lack of Standardization and Quality Control: The field is plagued by a lack of standardization in dosing, administration methods, and, most critically, the quality of the therapeutic agent itself. As exemplified by the failed Parkinson's disease trial, inconsistent or absent H₂ content in investigational products can render clinical trial results uninterpretable and lead to falsely negative conclusions.[11]
3. Dosing and Pharmacokinetics: Optimal dosing, frequency, and duration of H₂ therapy for various conditions have not been established. The rapid clearance of H₂ from the body necessitates further research into its "hit-and-run" pharmacodynamics to design effective treatment regimens.[12]
4. Limited Long-Term Clinical Data: The vast majority of human studies have been small-scale, short-term pilot trials. There is a pressing need for large, multicenter, long-term, randomized controlled trials to definitively establish efficacy and safety in specific patient populations.[21]

• Future Research Priorities:

1. Mechanistic Elucidation: Basic science research should prioritize the identification of H₂'s primary molecular binding partners and targets to move beyond descriptive phenomenology.
2. Formulation and Technology Development: A major focus must be on developing stable, verifiable, and standardized H₂ delivery systems—whether for inhalation, oral, or parenteral use—to ensure reproducible dosing in future clinical trials.
3. Targeted Clinical Trials: Future trials should be strategically focused on the most promising indications, particularly acute conditions like IRI, where the mechanism of action is most aligned with the pathophysiology.
4. Biomarker Development: Identifying reliable biomarkers that correlate with H₂ administration and therapeutic response would be invaluable for monitoring treatment and demonstrating biological effect in clinical studies.

6.3. Concluding Assessment of Therapeutic Potential

Molecular hydrogen stands as a molecule of immense therapeutic promise, yet its path to becoming a mainstream medical treatment is fraught with unique and significant challenges.

• Summary of Strengths: H₂'s therapeutic potential is rooted in a unique combination of highly desirable properties. It exerts broad-spectrum beneficial effects on fundamental pathological processes, including oxidative stress, inflammation, and apoptosis.[12] Its unparalleled ability to penetrate all tissues and subcellular compartments allows it to act where many other drugs cannot.[31] Crucially, it possesses an unparalleled safety profile, with no known pharmacological toxicity.[29]
• Summary of Challenges: The primary obstacles are not related to safety or efficacy in preclinical models, but rather to translation. These include the lack of a defined primary mechanism of action, the profound difficulties in formulating and administering a stable and consistent dose, mixed clinical evidence for chronic diseases, and a complex regulatory and economic landscape that discourages traditional pharmaceutical development.[10]
• Final Outlook: Molecular hydrogen challenges the conventional "one drug, one target, one disease" paradigm of modern pharmacology. Its pleiotropic effects and lack of a single, high-affinity target suggest it may function less like a classical drug and more like a "homeostatic regulator" or "redox adaptogen" that restores balance to stressed biological systems.[26] This novel paradigm may require new approaches to clinical validation and regulatory evaluation. The most viable near-term path for H₂ to achieve clinical integration likely lies in acute care settings—such as in surgery, emergency medicine, and organ transplantation—where its potent ability to mitigate ischemia-reperfusion injury can be leveraged to address clear unmet medical needs. For its broader potential in chronic diseases and wellness to be realized, the scientific and medical communities must first overcome the fundamental challenges of mechanistic understanding and standardized delivery. Without this foundational work, molecular hydrogen risks remaining a fascinating but clinically unfulfilled therapeutic agent.

Works cited

1. Hydrogen - the NIST WebBook - National Institute of Standards and Technology, accessed September 2, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=C1333740
2. Hydrogen | 1333-74-0 - ChemicalBook, accessed September 2, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7686195.htm
3. Hydrogen CAS#: 1333-74-0 - ChemicalBook, accessed September 2, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB7686195_EN.htm
4. Hydrogen = 99.99 1333-74-0 - Sigma-Aldrich, accessed September 2, 2025, https://www.sigmaaldrich.com/US/en/product/aldrich/295396
5. Hydrogen | H2 | CID 783 - PubChem, accessed September 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Hydrogen
6. Molecular Hydrogen in the Treatment of Respiratory Diseases - MDPI, accessed September 2, 2025, https://www.mdpi.com/1422-0067/26/9/4116
7. HYDROGEN | CAMEO Chemicals | NOAA, accessed September 2, 2025, https://cameochemicals.noaa.gov/chemical/8729
8. Anti‑inflammatory and antitumor action of hydrogen via reactive oxygen species (Review), accessed September 2, 2025, https://www.spandidos-publications.com/10.3892/ol.2018.9023
9. Anti-inflammatory and antitumor action of hydrogen via reactive oxygen species - PMC, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6096066/
10. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes - PMC, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10707987/
11. Molecular Hydrogen & Your Brain | Cognitive Vitality, accessed September 2, 2025, https://www.alzdiscovery.org/cognitive-vitality/ratings/molecular-hydrogen
12. Hydrogen, a Novel Therapeutic Molecule, Regulates ... - Frontiers, accessed September 2, 2025, https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.789507/full
13. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases | Oncotarget, accessed September 2, 2025, https://www.oncotarget.com/article/21130/text/
14. A comprehensive review of molecular hydrogen as a novel nutrition ..., accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11795818/
15. (PDF) Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/6345492_Hydrogen_acts_as_a_therapeutic_antioxidant_by_selectively_reducing_cytotoxic_oxygen_radicals
16. Molecular Hydrogen as a Novel Antioxidant: Overview of the Advantages of Hydrogen for Medical Applications | Request PDF - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/273326110_Molecular_Hydrogen_as_a_Novel_Antioxidant_Overview_of_the_Advantages_of_Hydrogen_for_Medical_Applications
17. Molecular hydrogen may activate the transcription factor Nrf2 to alleviate oxidative stress through the hydrogen-targeted porphyrin | Ohta | Aging Pathobiology and Therapeutics, accessed September 2, 2025, http://www.antpublisher.com/index.php/APT/article/view/566/700
18. Molecular Hydrogen as a Novel Therapeutic Tool in Situations of ..., accessed September 2, 2025, https://www.clinicsinoncology.com/full-text/cio-v2-id1367.php
19. Oxidative Stress and Pathways of Molecular Hydrogen Effects in Medicine - PubMed, accessed September 2, 2025, https://pubmed.ncbi.nlm.nih.gov/32954996/
20. Mechanisms of Hydrogen Therapy and its Application in SCI | DDDT - Dove Medical Press, accessed September 2, 2025, https://www.dovepress.com/the-molecular-biological-mechanism-of-hydrogen-therapy-and-its-applica-peer-reviewed-fulltext-article-DDDT
21. Molecular Hydrogen as Medicine: An Assessment of Administration ..., accessed September 2, 2025, https://www.mdpi.com/2673-4141/2/4/25
22. Hydrogen (H2) Alleviates Osteoarthritis by Inhibiting Apoptosis and Inflammation via the JNK Signaling Pathway - PubMed, accessed September 2, 2025, https://pubmed.ncbi.nlm.nih.gov/33880054/
23. Full article: The Molecular Biological Mechanism of Hydrogen Therapy and Its Application in Spinal Cord Injury - Taylor & Francis Online, accessed September 2, 2025, https://www.tandfonline.com/doi/full/10.2147/DDDT.S463177
24. Hydrogen-rich saline alleviates inflammation and apoptosis in myocardial I/R injury via PINK-mediated autophagy - PubMed Central, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6657957/
25. Pharmaceuticals | Special Issue : Therapeutic Potential of Molecular Hydrogen - MDPI, accessed September 2, 2025, https://www.mdpi.com/journal/pharmaceuticals/special_issues/2FPPQWNOTD
26. The Effects of 24-Week, High-Concentration Hydrogen-Rich Water ..., accessed September 2, 2025, https://www.dovepress.com/the-effects-of-24-week-high-concentration-hydrogen-rich-water-on-body--peer-reviewed-fulltext-article-DMSO
27. Hydrogen: A Rising Star in Gas Medicine as a Mitochondria-Targeting Nutrient via Activating Keap1-Nrf2 Antioxidant System - MDPI, accessed September 2, 2025, https://www.mdpi.com/2076-3921/12/12/2062
28. Molecular Hydrogen as a Novel Antitumor Agent: Possible Mechanisms Underlying Gene Expression - MDPI, accessed September 2, 2025, https://www.mdpi.com/1422-0067/22/16/8724
29. The Ultimate Guide to Molecular Hydrogen Use: 4 Methods of Administration - Dr. Antonucci, accessed September 2, 2025, https://drantonucci.com/biohacking/guide-to-molecular-hydrogen/
30. The On/Off History of Hydrogen in Medicine: Will the Interest Persist ..., accessed September 2, 2025, https://www.mdpi.com/2673-9801/3/1/11
31. Hydrogen, a Novel Therapeutic Molecule, Regulates Oxidative Stress, Inflammation, and Apoptosis - PMC - PubMed Central, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8721893/
32. Hydrogen - An Emerging Medical Gas | MHI, accessed September 2, 2025, https://molecularhydrogeninstitute.org/hydrogen-an-emerging-medical-gas/
33. Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults - PMC, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8505337/
34. Molecular Hydrogen: From Molecular Effects to Stem Cells Management and Tissue Regeneration - MDPI, accessed September 2, 2025, https://www.mdpi.com/2076-3921/12/3/636
35. Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application - PMC - PubMed Central, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12035766/
36. (PDF) The evolution of molecular hydrogen: A noteworthy potential therapy with clinical significance - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/236914565_The_evolution_of_molecular_hydrogen_A_noteworthy_potential_therapy_with_clinical_significance
37. Hydrogen Era - healthy Care Medical Group, accessed September 2, 2025, https://healthcare-h2era.com/en/hydrogen-era/
38. The Protective Role of Molecular Hydrogen in Ischemia/Reperfusion ..., accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11276695/
39. Paralysis agitans Terminated Phase 2 / 3 Trials for Hydrogen (DB15127) | DrugBank Online, accessed September 2, 2025, https://go.drugbank.com/indications/DBCOND0025481/clinical_trials/DB15127?phase=2%2C3&status=terminated
40. (PDF) THE APPLICABILITY OF MOLECULAR HYDROGEN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES: A BIBLIOGRAPHICAL REVIEW - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/389341491_THE_APPLICABILITY_OF_MOLECULAR_HYDROGEN_IN_THE_TREATMENT_OF_NEURODEGENERATIVE_DISEASES_A_BIBLIOGRAPHICAL_REVIEW
41. Molecular Hydrogen - Alzheimer's Drug Discovery Foundation, accessed September 2, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Molecular-Hydrogen-Cognitive-Vitality-For-Researchers.pdf
42. Hydrogen Completed Phase 1 Trials for Healthy Lifestyle Behaviors Screening - DrugBank, accessed September 2, 2025, https://go.drugbank.com/drugs/DB15127/clinical_trials?conditions=DBCOND0059969&phase=1&purpose=screening&status=completed
43. Autoimmune Disorder Unknown Status Phase 1 Trials ... - DrugBank, accessed September 2, 2025, https://go.drugbank.com/indications/DBCOND0041185/clinical_trials/DB15127?phase=1&status=unknown_status
44. Selumetinib Recruiting Phase 3 Trials for Low-Grade Glioma / Low Grade Astrocytomas / metastatic Low Grade Astrocytomas / metastatic Low Grade Glioma (LGG) Treatment | DrugBank Online, accessed September 2, 2025, https://go.drugbank.com/drugs/DB11689/clinical_trials?conditions=DBCOND0087390%2CDBCOND0071589%2CDBCOND0151346%2CDBCOND0151347&phase=3&purpose=treatment&status=recruiting
45. Hydrogen Completed Phase N/A Trials for Filariasis, Lymphatic / Soil Transmitted Helminth Infections | DrugBank Online, accessed September 2, 2025, https://go.drugbank.com/drugs/DB15127/clinical_trials?conditions=DBCOND0143540%2CDBCOND0064361&status=completed
46. Terbinafine Completed Phase 3 Trials for Onychomycosis Treatment | DrugBank Online, accessed September 2, 2025, https://go.drugbank.com/drugs/DB00857/clinical_trials?conditions=DBCOND0000154&phase=3&purpose=treatment&status=completed
47. Hydrogen-Rich Saline Protects Myocardium Against Ischemia/Reperfusion Injury in Rats | Request PDF - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/216015774_Hydrogen-Rich_Saline_Protects_Myocardium_Against_IschemiaReperfusion_Injury_in_Rats
48. Hydrogen gas inhalation protects against cutaneous ischaemia/reperfusion injury in a mouse model of pressure ulcer, accessed September 2, 2025, http://www.shmedmyco.com/Assets/userfiles/sys_eb538c1c-65ff-4e82-8e6a-a1ef01127fed/files/Hydrogen%20gas%20inhalation%20protects%20against%20cutaneous%20ischaemia_reperfusion%20injury%20in%20a.pdf
49. Redox Effects of Molecular Hydrogen and Its Therapeutic Efficacy in the Treatment of Neurodegenerative Diseases - MDPI, accessed September 2, 2025, https://www.mdpi.com/2227-9717/9/2/308
50. Effectiveness of Hydrogen Rich Water on Antioxidant Status of Subjects with Potential Metabolic Syndrome—An Open Label Pilot Study - J-Stage, accessed September 2, 2025, https://www.jstage.jst.go.jp/article/jcbn/46/2/46_09-100/_article
51. Therapeutic Potential of Molecular Hydrogen in Metabolic Diseases from Bench to Bedside - PMC - PubMed Central, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10141176/
52. REVIEW A Systematic Review of Molecular Hydrogen Therapy in Cancer Management, accessed September 2, 2025, https://journal.waocp.org/article_90474_620743d6f813062759db9772060a2d4c.pdf
53. Hydrogen Water: Health Benefits and Side Effects - WebMD, accessed September 2, 2025, https://www.webmd.com/diet/hydrogen-water-health-benefits
54. Is Molecular Hydrogen Safe? - Harmony Central, accessed September 2, 2025, https://harmonycentral-hk.com/blogs/molecular-hydrogen/is-molecular-hydrogen-safe
55. Does Hydrogen Water Have Side Effects? - AlkaWay, accessed September 2, 2025, https://www.alkaway.com.au/blog/does-hydrogen-water-have-side-effects/
56. Pilot feasibility and safety study of hydrogen gas inhalation in local - Dove Medical Press, accessed September 2, 2025, https://www.dovepress.com/pilot-feasibility-and-safety-study-of-hydrogen-gas-inhalation-in-local-peer-reviewed-fulltext-article-OTT
57. Hydrogen Water: Negative Side Effects and Considerations - One Green Filter, accessed September 2, 2025, https://onegreenfilter.com/hydrogen-water-negative-side-effects/
58. Hydrogen Water Negative Side Effects: What You Need to Know - HueLight, accessed September 2, 2025, https://hue-light.com/blog/hydrogen-water-side-effects/
59. Hydrogen Water: Does It Have Side Effects? - AlkaWay, accessed September 2, 2025, https://www.alkaway.com.au/blog/hydrogen-water-does-it-have-side-effects/
60. Is Hydrogen Inhalation Safe? Side Effects and Downsides | Suikatsu-Net, accessed September 2, 2025, https://h2info.jp/en/basics/safety/
61. When Not to Use Molecular Hydrogen as Therapy: Risks and ..., accessed September 2, 2025, https://www.osmiowater.eu/osmioblog/when-not-to-use-molecular-hydrogen-as-therapy-risks-and-considerations.html
62. Hydrogen peroxide poisoning: MedlinePlus Medical Encyclopedia, accessed September 2, 2025, https://medlineplus.gov/ency/article/002652.htm
63. Full article: A comprehensive review of treatments for hydrogen sulfide poisoning: past, present, and future, accessed September 2, 2025, https://www.tandfonline.com/doi/full/10.1080/15376516.2022.2121192
64. What are the benefits and risks of using molecular hydrogen (H2) therapy for medical treatment? - Dr.Oracle AI, accessed September 2, 2025, https://www.droracle.ai/articles/145089/benefits-of-molecular-hydrogen
65. GRAS Notices - cfsanappsexternal.fda.gov, accessed September 2, 2025, https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=520
66. Is Molecular Hydrogen Safe? - MHI, accessed September 2, 2025, https://molecularhydrogeninstitute.org/is-molecular-hydrogen-safe/
67. New FDA Labeling Requirements for Medical Gas Cylinders, accessed September 2, 2025, https://www.cganet.com/new-fda-labeling-requirements-for-medical-gas-cylinders/
68. Certification Process of Designated Medical Gases November 2015 - FDA, accessed September 2, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certification-process-designated-medical-gases
69. EMA Flexibilities, Authorities, and Mechanisms - Regulatory ... - NCBI, accessed September 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK609384/
70. European Medicines Agency (EMA), accessed September 2, 2025, https://www.ema.europa.eu/en/medicines
71. Medicinal gas marketing authorisation, accessed September 2, 2025, https://english.cbg-meb.nl/topics/mah-medicinal-gas
72. London, 9 July 2008 - European Medicines Agency, accessed September 2, 2025, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-medicinal-gases-pharmaceutical-documentation-including-recommendation-non-clinical-safety-requirements-well-established-medicinal-gases-revision-1_en.pdf
73. Sibnayal | European Medicines Agency (EMA), accessed September 2, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/sibnayal
74. EMEA-001884-PIP03-18 - paediatric investigation plan | European Medicines Agency (EMA), accessed September 2, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001884-pip03-18
75. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes - ResearchGate, accessed September 2, 2025, https://www.researchgate.net/publication/375988541_Molecular_Hydrogen_Therapy-A_Review_on_Clinical_Studies_and_Outcomes